Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
SVB Leerink Equities Analysts Reduce Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
05:32am, Friday, 01'st May 2020
Clovis Oncology (NASDAQ:CLVS) – Research analysts at SVB Leerink reduced their Q1 2020 EPS estimates for Clovis Oncology in a research note issued to investors on Monday, April 27th. SVB Leerink ana
Clovis Oncology (NASDAQ:CLVS) Cut to Hold at BidaskClub
10:32am, Thursday, 30'th Apr 2020
Clovis Oncology (NASDAQ:CLVS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, BidAskClub r
Clovis Oncology (NASDAQ:CLVS) Receives $17.56 Average Price Target from Brokerages
09:48am, Thursday, 30'th Apr 2020
Shares of Clovis Oncology (NASDAQ:CLVS) have received a consensus rating of “Hold” from the sixteen analysts that are presently covering the company, Marketbeat.com reports. Three analysts have ra
Clovis Oncology (NASDAQ:CLVS) Downgraded by SVB Leerink
08:26am, Thursday, 30'th Apr 2020
SVB Leerink cut shares of Clovis Oncology (NASDAQ:CLVS) from a market perform rating to an underperform rating in a research report sent to investors on Monday morning, Benzinga reports. The firm curr
U.S. FDA gives broader approval to GSK's Zejula for ovarian cancer
08:11pm, Wednesday, 29'th Apr 2020
The U.S. Food and Drug Administration on Wednesday cleared expanded use of GlaxoSmithKline Plc's Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemothe
U.S. FDA gives broader approval to GSK’s Zejula for ovarian cancer
08:08pm, Wednesday, 29'th Apr 2020
The U.S. Food and Drug Administration on Wednesday cleared expanded use of GlaxoSmithKline Plc’s Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to…
U.S. FDA gives broader approval to GSK's Zejula for ovarian cancer
08:05pm, Wednesday, 29'th Apr 2020
The U.S. Food and Drug Administration on Wednesday cleared expanded use of GlaxoSmithKline Plc's Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemothe
Clovis Oncology to Present at the Bank of America Health Care Conference 2020
08:05pm, Wednesday, 29'th Apr 2020
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday, May
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
04:34pm, Tuesday, 28'th Apr 2020
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
04:34pm, Tuesday, 28'th Apr 2020
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis Oncology (NASDAQ:CLVS) Stock Price Down 9.5%
06:48am, Tuesday, 28'th Apr 2020
Shares of Clovis Oncology (NASDAQ:CLVS) fell 9.5% on Monday . The company traded as low as $8.10 and last traded at $8.17, 6,168,184 shares changed hands during trading. A decline of 15% from the aver
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
12:00am, Tuesday, 28'th Apr 2020Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
05:17pm, Monday, 27'th Apr 2020
Strong clinical trial results from AstraZeneca and Merck just made it harder for Clovis Oncology to reach profitability.
's Top Upgrades, Downgrades For April 27, 2020
01:32pm, Monday, 27'th Apr 2020
Upgrades
For Alliance Data Systems Corp (NYSE: ADS), Compass Point upgraded the stock from Neutral to Buy. Alliance Data Systems earned $0.75 in the first quarter...
